The above data suggest that RIG-I is specifically upregulated in tumour-infiltrating CD8+ T cells and may function as a novel intracellular checkpoint that negatively regulates the anti-tumour activity of CD8+ T cells. This evidence concerns the gene RIGI and neoplasm.